GOTHENBURG, Sweden, May 8, 2025 /PRNewswire/ -- The Vitrolife Group today announces it has become a leading investor in AutoIVF. This strategic investment aligns with our corporate strategy of improving affordability and access to IVF to patients around the world.

AutoIVF, is an early-stage MedTech company with the aim to make IVF more accessible, affordable and efficient. Its technology, OvaReady™, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation, enabling high-quality fertility services in the current IVF process and also supports decentralising the egg retrieval process outside traditional IVF laboratory settings. ''This investment marks another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care," says Bronwyn Brophy O'Connor, CEO of the Vitrolife Group.Ravi Kapur, CEO of AutoIVF, shares, "With this new investment and partnership, we are excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem."Financial impact is minimal, more details will be disclosed during the Q2 earnings release.Gothenburg, May 8, 2025 VITROLIFE AB (publ)Bronwyn Brophy O'Connor, CEO

GOTHENBURG, Sweden, April 30, 2025 /PRNewswire/ -- At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:

Resolution in accordance with the Board's proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.Remuneration to the Board members is proposed to be in total SEK 3 670 000 (3 300 000) of which SEK 1 350 000 (1 200 000) to the Chairman of the Board, SEK 450 000 (400 000) to each of the other members of the Board, SEK 160 000 (150 000) to the Chairman of the Audit Committee and SEK 80 000 (75 000) to each of the other members of the Audit Committee.Re-election of Deloitte AB as auditor with unchanged remuneration principles.Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.Implementation of a share-based incentive program including issue of a maximum number of 480,000 warrants to a wholly owned subsidiary of Vitrolife AB and approval that the subsidiary may transfer shares and/or warrants and of hedging activities.

GOTHENBURG, Sweden, April 29, 2025 /PRNewswire/ -- At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:

Resolution in accordance with the Board's proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.Remuneration to the Board members is proposed to be in total SEK 3 670 000 (3 300 000) of which SEK 1 350 000 (1 200 000) to the Chairman of the Board, SEK 450 000 (400 000) to each of the other members of the Board, SEK 160 000 (150 000) to the Chairman of the Audit Committee and SEK 80 000 (75 000) to each of the other members of the Audit Committee. The Election Committee proposes re-election of the auditor Deloitte AB and with unchanged remuneration principles.Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital. Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company. The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.Resolution to entering a share swap agreement in order to secure delivery of shares to participants in LTIP 2025 and the potential financial impacts of LTIP 2025.             

GOTHENBURG, Sweden, April 24, 2025 /PRNewswire/ --

First quarter

Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. Gross margin increased to 57.4% (57.1).Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. Operating cash flow amounted to SEK 69 million (198). Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85).

GOTHENBURG, Sweden, April 10, 2025 /PRNewswire/ -- Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master's degree in business administration. 

GOTHENBURG, Sweden, April 10, 2025 /PRNewswire/ -- Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q1 2025. The presentation will be held in English.

Time: Thursday 24 April, 2025 at 10.00 a.m. CET. 

To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy

GOTHENBURG, Sweden, March 31, 2025 /PRNewswire/ -- To further drive the execution of the Vitrolife Group corporate strategy, the company is evolving the executive management team and introducing a SVP Innovation role to accelerate the pace and output of innovation. 

Rickard Ericsson, formerly SVP Consumables and prior to that SVP Sales & Marketing, is appointed SVP Innovation, effective immediately. Rickard has been with the company for over ten years and has a deep understanding of the reproductive-health market, the evolving trends and customer needs. In this role, he will oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management and Market Access.

GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Vitrolife Group has today published its Annual and Sustainability Report for 2024.

The Annual and Sustainability Report is now available digitally in English and Swedish at www.vitrolifegroup.com. The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish.

Vitrolife Group has chosen not to print or distribute a hard copy of the Annual Report. Those who are unable to access the Annual Report digitally can request a print-out of the Annual Report by contacting Vitrolife Group at investors@vitrolife.com or call +46 (0) 31 721 80 00.

GOTHENBURG, Sweden, March 25, 2025 /PRNewswire/ -- The shareholders of Vitrolife AB (publ) are hereby invited to attend the Annual General Meeting of shareholders on 29 April 2025 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. The entrance opens at 3.30 pm. 

Shareholders who wish to attend the Annual General Meeting must:- be recorded in the share register prepared by Euroclear Sweden AB relating to the circumstances on 17 April 2025; and- notify their attendance in accordance with the instructions in the Notice by 23 April 2025. 

GOTHENBURG, Sweden, March 5, 2025 /PRNewswire/ -- Vitrolife Group is aware that a PGT-A class action lawsuit has been filed against Vitrolife AB (publ), Vitrolife Inc and Igenomix USA, Inc in the court of the Southern District of Florida, although no formal complaint has been served yet. During the fourth quarter of 2024, similar class actions were initiated in the US against other peer companies providing PGT-A testing services. Vitrolife Group will, together with our legal counsel in the US, evaluate the class action and its potential scope and update the market in due course when further information is available.